Kinetics of natural and acquired immunity to typhoid fever by Pulickal, A, Pulickal, Anoop Sebastian

Subjects:

Progress in the overall understanding of typhoid fever: implications for vaccine development by O'Reilly, PJ, Pant, D, Shakya, M, Basnyat, B, Pollard, A

“…Introduction: Typhoid fever continues to have a substantial impact on human health, especially in Asia and sub-Saharan Africa. …”

Immunogenicity and efficacy of conjugated and unconjugated Vi-polysaccharide vaccines in the prevention of typhoid fever by Jin, C

“…<p>Each year, 12.1 to 20.6 million typhoid fever infections occur globally, of which 1% result in death. …”

Understanding typhoid disease; a controlled human infection model of typhoid fever by Waddington, C, Claire Waddington

“…This DPhil described the development of a human challenge model of typhoid fever using <en>S</en></p>. Typhi Quailes strain administered to healthy adults in a sodium bicarbonate buffer. …”

Interferon-driven alterations of the host’s amino acid metabolism in the pathogenesis of typhoid fever by Blohmke, C, Darton, T, Jones, C, Suarez, N, Angus, B, Zhou, L, Hill, J, Clare, S, Kane, L, Mukhopadhyay, S, Schreiber, F, Duque-Correa, M, Wright, J, Roumeliotis, T, Yu, L, Choudhary, J, Mejias, A, Ramilo, O, Shanyinde, M, Sztein, M, Kingsley, R, Lockhart, S, Levine, M, Lynn, D, Dougan, G, Pollard, A

“…Corresponding alterations in tryptophan catabolites with immunomodulatory properties in serum of participants with typhoid fever confirmed the activity of this pathway, and implicate a central role of host tryptophan metabolism in the pathogenesis of typhoid fever.…”

Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model by Gibani, M, Jones, E, Barton, A, Jin, C, Meek, J, Camara, S, Galal, U, Heinz, E, Rosenberg-Hasson, Y, Obermoser, G, Jones, C, Campbell, D, Black, C, Thomaides-Brears, H, Darlow, C, Dold, C, Silva-Reyes, L, Blackwell, L, Lara-Tejero, M, Jiao, X, Stack, G, Blohmke, C, Hill, J, Angus, B, Dougan, G, Galán, J, Pollard, A

“…Salmonella Typhi is a human host-restricted pathogen that is responsible for typhoid fever in approximately 10.9 million people annually1. …”

Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype? by Pulickal, A, Pollard, A

An evaluation of purified Salmonella Typhi protein antigens for the serological diagnosis of acute typhoid fever by Tran Vu Thieu, N, Trinh Van, T, Tran Tuan, A, Klemm, E, Nguyen Ngoc Minh, C, Voong Vinh, P, Pham Thanh, D, Ho Ngoc Dan, T, Pham Duc, T, Langat, P, Martin, L, Galan, J, Liang, L, Felgner, P, Davies, D, de Jong, H, Maude, R, Fukushima, M, Wijedoru, L, Ghose, A, Samad, R, Dondorp, A, Faiz, A, Darton, T, Pollard, A, Thwaites, G, Dougan, G, Parry, C, Baker, S

“…<p>OBJECTIVES: The diagnosis of typhoid fever is a challenge. Aiming to develop a typhoid diagnostic we measured antibody responses against Salmonella Typhi (S. …”

Identification of novel serodiagnostic signatures of typhoid fever using a salmonella proteome array by Darton, T, Baker, S, Randall, A, Dongol, S, Karkey, A, Voysey, M, Carter, M, Jones, C, Trappl, K, Pablo, J, Hung, C, Teng, A, Shandling, A, Le, T, Walker, C, Molina, D, Andrews, J, Arjyal, A, Basnyat, B, Pollard, A, Blohmke, C

“…Current diagnostic tests for typhoid fever, the disease caused by Salmonella Typhi, are poor. …”

Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype? by Pulickal, A, Pollard, A

Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies by Waddington, C, Waddington, C, Darton, T, Darton, T, Woodward, W, Angus, B, Levine, M, Pollard, A, Pollard, A

Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. by Waddington, C, Darton, T, Woodward, W, Angus, B, Levine, M, Pollard, A

Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal by Shakya, M

Subjects: “…Typhoid fever…”

Importance of Salmonella Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model by Fresnay, S, McArthur, M, Magder, L, Darton, T, Jones, C, Waddington, C, Blohmke, C, Angus, B, Levine, M, Pollard, A, Sztein, M

“…Typhoid fever, caused by the human-restricted organism Salmonella enterica serovar Typhi (S. …”

Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans by Fresnay, S, McArthur, M, Magder, L, Darton, T, Jones, C, Waddington, C, Blohmke, C, Angus, B, Levine, M, Pollard, A, Sztein, M

“… <p style="text-align:justify;"><b>Background:</b> Typhoid fever, caused by the human-restricted organism Salmonella Typhi (S. …”

Salmonella typhi bactericidal antibodies reduce disease severity but do not protect against typhoid fever in a controlled human infection model by Juel, H, Thomaides-Brears, H, Darton, T, Jones, C, Jones, E, Shrestha, S, Sie, R, Eustace, A, Galal, U, Kurupati, P, Van, T, Thieu, N, Baker, S, Blohmke, C, Pollard, A

Blood culture-PCR to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. by Darton, T, Zhou, L, Blohmke, C, Jones, C, Waddington, C, Baker, S, Pollard, A

IgA and IgG1 specific to vi polysaccharide of salmonella typhi correlate with protection status in a typhoid fever controlled human infection model by Dahora, L, Jin, C, Spreng, R, Feely, F, Mathura, R, Seaton, K, Zhang, L, Hill, J, Jones, E, Alam, S, Dennison, S, Pollard, A, Tomaras, G

“…Vaccination against Salmonella Typhi using the Vi capsular polysaccharide, a T-cell independent antigen, can protect from the development of typhoid fever. This implies that antibodies to Vi alone can protect in the absence of a T cell-mediated immune response; however, protective Vi antibodies have not been well-characterized. …”

Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial by Jin, C, Gibani, M, Moore, M, Juel, H, Jones, E, Meiring, J, Harris, V, Gardner, J, Nebykova, A, Kerridge, S, Hill, J, Thomaides-Brears, H, Blohmke, C, Yu, l, Angus, B, Pollard, A

“…Vi-TT use has the potential to reduce both the burden of typhoid fever and associated health inequality.The Bill &amp; Melinda Gates Foundation and the European Commission FP7 grant, Advanced Immunization Technologies (ADITEC).…”

Signatures of cellular immunity after vaccination and challenge that associate with clinical outcome of Salmonella Typhi infection by Cross, D

“…Typhi), the aetiological cause of typhoid fever, is responsible for up to 20.6 million infections every year, the majority of which occur in children under 15 years of age. …”